Cancer Advances is a company led by an experienced team with more than 100 years
of combined industry experience.

Our Story



Cancer Advances was created as a wholly owned subsidiary of Cato BioVentures to acquire all the technology and intellectual property for a novel vaccine, PAS (Polyclonal Antibody Stimulator). PAS functions by stimulating the immune system in the patient to produce endogenous polyclonal antibodies to gastrin, without the risks and limitations associated with serum-derived polyclonal treatment or monoclonal antibody therapy. PAS was discovered and developed by scientists at Aphton Corporation, acquired by Receptor Biologix and then by Cancer Advances. Currently, Cancer Advances is focused on developing PAS therapeutics for gastric, pancreatic and other cancers, and identifying synergy between treatment classes.

The company has developed an intellectual property strategy that holds over 100 United States and worldwide patents related to PAS. In addition, Cancer Advances has a trademark portfolio and strategy for pursuing other trademarks.



Executive Team



Allen Cato, Chief Executive Officer and Chief Medical Officer

Allen Cato, Chief Executive Officer and Chief Medical OfficerAllen Cato, M.D., Ph.D. cofounded Cato Research and Cato BioVentures and has more than 40 years of experience in clinical study design, regulatory interactions, adverse drug reactions, and clinical research and new drug development. He has directed or participated in the development of more than 100 INDs and NDAs. Dr. Cato has published more than 100 papers, principally in the field of clinical pharmaceutical research, and he participates as a member of the board of directors for several pharmaceutical and biotechnology companies.



Lynda Sutton, President

Lynda Sutton, President and SecretaryLynda Sutton, B.S. currently serves as the President and Chief Regulatory Officer for Cato Research, and President for Cancer Advances. Ms. Sutton has 25 years of experience in the drug development industry, specializing in the development of regulatory strategies for drugs and biologics. She has coordinated activities in various disciplines and has been involved in the development of new clinical entities, has overseen the preparation of FDA pre-meeting submissions, and has ensured that regulatory requirements necessary for the approval and launch of new products have been satisfied. She has served as the primary regulatory contact for more than 100 Biotech and pharmaceutical companies over the last 19 years. In addition, Ms. Sutton has cofounded several small biotechnology companies and serves as a member of the board of directors for several companies. She has expertise in the development of biological products, with emphasis on gene therapy and blood products, and in the development of oncological, anti-infective, and neuropharmacological products.


John Wingen, CFO

John Wingen, CFO8+ years experience in the drug development industry in finance and operational roles









Scientific Advisor



Jill P. Smith, M.D., Director of Clinical Gastroenterology and Oncology

Jill P. Smith, M.D.Jill P. Smith, M.D., Director of Clinical Gastroenterology and Oncology for Cato Research, is a clinician scientist who is Board certified in Gastroenterology. She is a leading researcher in the field of Pancreatology and former President of the American Pancreas Association. She is the recipient of the European Basic Science research award for pancreas research. Dr. Smith served as the Director of Clinical and Translational Research in NIDDK at the National Institutes of Health until January 2018. As an independent researcher she has expertise in bench to bedside translational research, and FDA regulation. In October 2013 she served as the Moderator of the FDA GREAT-2 conference on conducting clinical trials in gastrointestinal disorders. Currently she is Full Professor at Georgetown University in Washington DC in the Department of Medicine, Division of Gastroenterology & Hepatology.



Operational Team



Teresa Phillips, Director of Development

Teresa Phillips, Director of Development25 + years pharmaceutical research experience









Katy Kuipers, Business Development

Katy Kuipers, Business Development19+ years pharma experience, past affiliations include Eisai Inc. & OSI Pharmaceuticals









Partners and Subsidiaries


Vaccicure Limited